Previous 10 | Next 10 |
The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Investor Presentation - Slideshow
Arcellx Appoints Olivia Ware to Board of Directors PR Newswire -- Replaces Lewis T. "Rusty" Williams, M.D., on Board of Directors -- FOSTER CITY, Calif. , May 16, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagin...
Arcellx press release (NASDAQ:ACLX): Q1 GAAP EPS of -$1.56 misses by $0.46. As of March 31, 2022, Arcellx had cash, cash equivalents, and marketable securities of $210.9 million, which is anticipated to fund its operations into the second half of 2023. For further details see: Arcellx G...
Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results PR Newswire -- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory multiple myeloma (r/r MM) -...
Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma PR Newswire -- ARC-SparX is a...
Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma PR Newswire 100% ORR ; 75% CR/sCR; and evidence of durable clinical benefit ...
Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference PR Newswire FOSTER CITY, Calif. , May 5, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of ...
Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire -- Company to host a live webc...
Arcellx (ACLX) shares jumped 12% on Monday following a week of declines. Shares of the biotech group opened at $11.23 and hit a high of $11.97 in early afternoon. The stock recently changed hands at $11.94, up 12%, at approximately 1:15 p.m. Based in Maryland, Arcellx has been developing cell...
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting PR Newswire -- ACLX-002 completely regresses multiple c...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...